Deep venous thrombosis after high-dose intravenous immunoglobulin in the treatment of pemphigus vulgaris

Daniel J Sheehan, Jack L. Lesher

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

A 43-year-old black man with pemphigus vulgaris was started on intravenous immunoglobulin (IVIg) therapy after his disease was found to be refractory to prednisone alone and prednisone in combination with mycophenolate mofetil, azathioprine, methotrexate, cyclosporine, and oral cyclophosphamide. The patient subsequently developed a deep venous thrombosis (DVT) that was attributed to the IVIg. IVIg has been associated with numerous thrombotic complications such as pulmonary embolism and myocardial infarction. Traditional risk factors for thrombotic complications, such as hypertension, a history of coronary artery disease, and immobility, should be considered as relative contraindications to IVIg therapy.

Original languageEnglish (US)
Pages (from-to)403-406
Number of pages4
JournalCutis
Volume73
Issue number6
StatePublished - Jun 1 2004

Fingerprint

Pemphigus
Intravenous Immunoglobulins
Venous Thrombosis
Passive Immunization
Prednisone
Pulmonary Infarction
Mycophenolic Acid
Azathioprine
Therapeutics
Pulmonary Embolism
Methotrexate
Cyclophosphamide
Cyclosporine
Coronary Artery Disease
Myocardial Infarction
Hypertension

ASJC Scopus subject areas

  • Dermatology
  • Immunology and Allergy

Cite this

Deep venous thrombosis after high-dose intravenous immunoglobulin in the treatment of pemphigus vulgaris. / Sheehan, Daniel J; Lesher, Jack L.

In: Cutis, Vol. 73, No. 6, 01.06.2004, p. 403-406.

Research output: Contribution to journalReview article

@article{e6d362c2c0fe4a2699e71defade02213,
title = "Deep venous thrombosis after high-dose intravenous immunoglobulin in the treatment of pemphigus vulgaris",
abstract = "A 43-year-old black man with pemphigus vulgaris was started on intravenous immunoglobulin (IVIg) therapy after his disease was found to be refractory to prednisone alone and prednisone in combination with mycophenolate mofetil, azathioprine, methotrexate, cyclosporine, and oral cyclophosphamide. The patient subsequently developed a deep venous thrombosis (DVT) that was attributed to the IVIg. IVIg has been associated with numerous thrombotic complications such as pulmonary embolism and myocardial infarction. Traditional risk factors for thrombotic complications, such as hypertension, a history of coronary artery disease, and immobility, should be considered as relative contraindications to IVIg therapy.",
author = "Sheehan, {Daniel J} and Lesher, {Jack L.}",
year = "2004",
month = "6",
day = "1",
language = "English (US)",
volume = "73",
pages = "403--406",
journal = "Cutis",
issn = "0011-4162",
publisher = "Quadrant Healthcom Inc.",
number = "6",

}

TY - JOUR

T1 - Deep venous thrombosis after high-dose intravenous immunoglobulin in the treatment of pemphigus vulgaris

AU - Sheehan, Daniel J

AU - Lesher, Jack L.

PY - 2004/6/1

Y1 - 2004/6/1

N2 - A 43-year-old black man with pemphigus vulgaris was started on intravenous immunoglobulin (IVIg) therapy after his disease was found to be refractory to prednisone alone and prednisone in combination with mycophenolate mofetil, azathioprine, methotrexate, cyclosporine, and oral cyclophosphamide. The patient subsequently developed a deep venous thrombosis (DVT) that was attributed to the IVIg. IVIg has been associated with numerous thrombotic complications such as pulmonary embolism and myocardial infarction. Traditional risk factors for thrombotic complications, such as hypertension, a history of coronary artery disease, and immobility, should be considered as relative contraindications to IVIg therapy.

AB - A 43-year-old black man with pemphigus vulgaris was started on intravenous immunoglobulin (IVIg) therapy after his disease was found to be refractory to prednisone alone and prednisone in combination with mycophenolate mofetil, azathioprine, methotrexate, cyclosporine, and oral cyclophosphamide. The patient subsequently developed a deep venous thrombosis (DVT) that was attributed to the IVIg. IVIg has been associated with numerous thrombotic complications such as pulmonary embolism and myocardial infarction. Traditional risk factors for thrombotic complications, such as hypertension, a history of coronary artery disease, and immobility, should be considered as relative contraindications to IVIg therapy.

UR - http://www.scopus.com/inward/record.url?scp=3042566866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042566866&partnerID=8YFLogxK

M3 - Review article

VL - 73

SP - 403

EP - 406

JO - Cutis

JF - Cutis

SN - 0011-4162

IS - 6

ER -